Abstracts

Filters

Clear Filters
All Days Sun, Sep 27 Mon, Sep 28 Tue, Sep 29 Wed, Sep 30

Monday, September 28

11:05 AM - 11:15 AM ET

185 - Repeat Catheter Ablation vs. Stereotactic Arrhythmia Radioablation for Recurrent Ventricular Tachycardia in Structural Heart Disease: The STAR-VT-2020 Randomized Trial
Speaker: Cvek, Jakub, MD, PhD - University Hospital Ostrava, Ostrava, Ceská republika
11:05 AM - 11:15 AM ET

192 - Estimating Neurocognitive Failure in the Presence of Competing Mortality: Kaplan-Meier and Competing-Risk Analyses from NRG CC001
Speaker: Zarinshenas, Reza, MD - University of Maryland Radiation Oncology, Baltimore, MD
11:05 AM - 11:15 AM ET

199 - Early Adaptive Interventions in Lung Cancer: Leveraging Fusion of Longitudinal CBCT Trajectories and Clinical Variables for Robust Survival Prediction
Speaker: Choi, Wookjin, PhD - Thomas Jefferson University, Philadelphia, PA
11:05 AM - 11:15 AM ET

205 - 30Gy vs 40Gy Consolidative Radiotherapy for Limited-Stage Diffuse Large B cell Lymphoma Achieving Complete Remission after Chemotherapy: A Randomized, Open-Label, Non-Inferiority, Multicenter Phase 3 Clinical Trial
Speaker: Liu, Xin, MD - State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PU, Beijing
11:15 AM - 11:25 AM ET

168 - Immunotherapy Based Total Neoadjuvant Therapy with or without Short-Course Radiotherapy for Locally Advanced Rectal Cancer: Initial Results of TORCH-iTNT
Speaker: Wang, Yaqi, MD - Fudan University Shanghai Cancer Center, Shanghai, Shanghai
11:15 AM - 11:25 AM ET

174 - Secondary Immunological Analysis of a Prospective Trial in Patients with Recurrent Head and Neck Malignancies
Speaker: Unnikrishnan, Soumya, MD, MS - Winship Cancer Institute of Emory University, Atlanta, GA
11:15 AM - 11:25 AM ET

180 - Firmonertinib plus Radiotherapy vs. Concurrent Chemoradiotherapy followed by Firmonertinib Consolidation in Unresectable Stage III <em>EGFR</em>-mutant NSCLC: A Randomized Phase 2 Trial
Speaker: Wang, Linlin - Cancer Hospital of Shangdong First Medical University, Jinan
11:15 AM - 11:25 AM ET

186 - Quality of Life and Toxicities Following Whole-Palm vs. Involved-Field Radiotherapy for Dupuytren's Disease: A Sub-Study from a Randomized Trial
Speaker: Martin, Jarad, MB, ChB, PhD, DMed(Research) BSc FRANZCR GAustMS - Calvary Mater Newcastle Hospital, Newcastle, NSW
11:15 AM - 11:25 AM ET

193 - Closing the Screening Gap: A Survivor-Led Model for Early Oral Cancer Detection in Rural India
Speaker: Sai Shreya, Vangipuram, MBBS - Sri Rama Chandra Medical College, Chennai
11:15 AM - 11:25 AM ET

200 - Radiological prior Knowledge-Guided Deep Learning for Predicting Invasiveness of Medium-Sized Pulmonary Nodules
Speaker: Huang, Canbo - Institute of Radiation Medicine, Fudan University, Shanghai, Shanghai
11:15 AM - 11:25 AM ET

206 - Safety of Maintenance Pembrolizumab (Pembro) and Concurrent Radiotherapy (RT) in Pediatric Participants with Classic Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Front-Line Chemotherapy (Chemo): Post Hoc Analysis of the KEYNOTE-667 Study
Speaker: Hoppe, Bradford, MD, FASTRO, MPH - Mayo Clinic Florida, Jacksonville, FL
11:25 AM - 11:35 AM ET

169 - A Novel Regimen of Liposomal Irinotecan Plus Capecitabine as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LipCap): A Phase II Trial
Speaker: Xiao, Linlin, MS, RT - the fourth hospital of hebei medical university, Shijiazhuang, Hebei province